Stoke Therapeutics Inc STOK

$26.54 +0.47 (1.80%)

Valuation

Market cap
1,735,875,000
Revenue TTM
$184,420,000
Net income TTM
$-6,890,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-3.74%
Debt to equity
0.00

Trading

Volume
1,162,600
Avg volume
1,094,404
Day's range
$25.96 – $26.72
Shares out
65,406,000
Stochastic %K
52%
Beta
1.36
Analysts
Strong Buy
Price target
$46.36

Price

Company profile

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of au...

Show more

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 430 8200
Website
https://www.stoketherapeutics.com
Address
45 Wiggins Avenue, Bedford, United States

Latest news

Stocktwits

Merlintrader Nov 3, 1:50 PM
Stoke Therapeutics $STOK will present at two investor conferences in November. CEO Ian F. Smith and Chief Patient Officer Jason Hoitt present on Nov 10 in Boston (1:00 p.m. ET) and Nov 17 in London (11:00 a.m. ET). Shares closed at $26.48 on Monday, below the SMA50 and below the SMA200, RSI 74. More details in our hub. Not investment advice.
0 replies
Merlintrader Nov 1, 8:38 PM
Oct 29: Q3 update. EMPEROR Phase 3 readout for zorevunersen expected Q3 2027, NDA planned 2H 2027; cash $358.8M, runway into early 2028. $STOK closed the week at $26.29 (+5.0% w/w), below the 50-day SMA ($27.43) and below the 200-day ($30.92). RSI14 52.3. 20-day range $22.05-$27.22. STOK Stock Hub: Stoke Therapeutics News, Zorevunersen and RNA Medicines https://www.merlintrader.com/stoke-therapeutics-stock-hub/
0 replies
Merlintrader Nov 1, 9:06 AM
$PRAX $RAPP $STOK $XENE Epilepsy beyond seizure counts: new sector report Praxis (relutrigine in SCN2A/SCN8A DEEs), Rapport (RAP-219 in focal seizures), Stoke (zorevunersen in Dravet syndrome) and Xenon (azetukalner application). The report separates seizure reduction from disease modification and looks at treatment burden, regulatory calendars and cash needs. https://www.merlintrader.com/epilepsy-beyond-seizure-counts-prax-rapp-stok-xene/
1 replies
EliteMr Oct 30, 11:40 PM
$STOK
0 replies
EarningsInsider Oct 29, 9:46 PM
https://www.marketbeat.com/earnings/reports/2026-10-29-stoke-therapeutics-inc-stock/ $STOK Stoke Therapeutics Earnings Transcript
0 replies
StocktwitsEarnings Oct 29, 8:10 PM
$STOK Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.08 down -66.15% YoY • Reported revenue of $11.26M up 5.93% YoY • Stoke Therapeutics said its $358.8M in cash, cash equivalents and marketable securities as of September 30, 2026 is expected to fund operations into early 2028.
0 replies
shoc24 Oct 29, 5:24 PM
$STOK reports earnings today after the close. I used Stock Meadow’s earnings dashboard to review its history: STOK has beaten EPS estimates in 5 of its last 8 reports.
0 replies
Merlintrader Oct 29, 8:36 AM
$STOK Stoke Therapeutics: Q3 business and financial update today after the close. Watch zorevunersen (Dravet syndrome) Phase 3 progress and cash. Live webcast today, Thu Oct 29, at 4:30 p.m. ET: https://investor.stoketherapeutics.com/ $STOK closed at $26.41 on Wednesday, below the 50-day SMA ($27.66) and below the 200-day ($30.96). Daily RSI 53. STOK hub: https://www.merlintrader.com/stoke-therapeutics-stock-hub/ Interactive chart with bull and bear scenarios on JC Just Charts: https://justcharts.merlintrader.com/#STOK Not investment advice.
0 replies